Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Chin Peter Scott 2. Date of Event Requiring Statement (Month/Day/Year) 04/10/2026 3. Issuer Name and Ticker or Trading Symbol Denali Therapeutics Inc. [DNLI] (Last) (First) (Middle) C/O DENALI THERAPEUTICS INC., 161 OYSTER POINT BOULEVARD, SECOND FLOOR 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Medical Officer 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) SOUTH SAN FRANCISCO, CA 94080 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 170,612(1)(2) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(3)	05/10/2029	Common Stock	43,000	$22.31	D
Stock Option (right to buy)	(3)	02/10/2030	Common Stock	35,100	$24.81	D
Stock Option (right to buy)	(3)	01/10/2031	Common Stock	14,250	$80.03	D
Stock Option (right to buy)	(3)	01/03/2032	Common Stock	13,000	$47.27	D
Stock Option (right to buy)	(3)	02/03/2032	Common Stock	10,250	$33.74	D
Stock Option (right to buy)	(4)	01/03/2033	Common Stock	32,900	$27.63	D
Stock Option (right to buy)	(5)	01/03/2034	Common Stock	44,750	$20.33	D
Stock Option (right to buy)	(6)	01/03/2035	Common Stock	40,650	$21.26	D
Stock Option (right to buy)	(7)	03/20/2036	Common Stock	63,800	$20.17	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Chin Peter Scott C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BOULEVARD, SECOND FLOOR SOUTH SAN FRANCISCO, CA 94080			Chief Medical Officer

Signatures

/s/ Tyler Nielsen, by power of attorney		04/20/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Includes 2,326 shares acquired under the Denali ESPP.
(2)	Includes 145,845 Unvested RSU's.
(3)	The shares subject to the option are fully vested and exercisable.
(4)	25% of the shares subject to the option vested on January 3, 2024 and an additional 1/48 of the shares vested monthly thereafter.
(5)	25% of the shares subject to the option vested on January 3, 2025 and an additional 1/48 of the shares vest monthly thereafter.
(6)	25% of the shares subject to the option vested on January 3, 2026 and an additional 1/48 of the shares vest monthly thereafter.
(7)	25% of the shares subject to the option will vest on January 3, 2027 and an additional 1/48 of the shares vest monthly thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.